CT041-ST-01
Regimen
- Experimental
- satri-cel (CLDN18.2-directed CAR-T)
- Control
- physician's choice chemotherapy
Population
CLDN18.2-positive (IHC >=2+, >=40% cells) advanced G/GEJ cancer refractory to >=2 prior lines
Key finding
mPFS 3.25 vs 1.77 mo (HR 0.37, 95% CI 0.25-0.55, p<0.0001); ORR 37% vs 10%; mOS trend favorable (data maturing)
Source: PMID 40460847
Timeline
Guideline citations
- CSCO GASTRIC 2025 (p.80)⚠️ OCR source